French pharma company Pierre Fabre Laboratories has baged Vertical Bio to push development of the company’s NSCLC candidate.
C
French-US-based investment specialist Lauxera Capital Partners announced today that it has invested €17m in Swedish cell culture company BioLamina AB (BioLamina)
Orano Med SAS and Orbit Discovery Ltd announced a collaboration to develop Peptide Receptor Radionuclide Therapies for cancer cells and develop novel radiopharmaceuticals.
Non-profit foundation BioInnovation Institute (BII) has unveiled its latest commitment to driving innovation and growth within the life science sector. Six promising companies will receive crucial financial support through BII’s Venture House programme.
At a council meeting, a majority of EU agriculture ministers have supported the draft regulation on new genomic technologies (NGT) proposed by the EU Commission in early July.
German researchers have developed a new way to detect the about 300 cullin-RING ligases (CRLs) which specifically trigger destruction of specific proteins in the cell.
According to Swiss bioethicists, deregulation of genetic engineering rules for plants optimised through targeted mutation and cisgenetics will make little contribution to climate protection by 2050.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of globally accessible vaccines against endemic outbreaks.
Bayer and Pairwise extend their collaboration in precision breeding for five further years to develop CRISPR applications for Bayer’s Preceon Smart Corn System.
Mysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune indications. The focus is on pan-PIM kinase inhibitors that uniquely modulate multilineage immune cell functions.